Merocef 125 mg/5 ml (Powder for Suspension)

70 ml bottle: ৳ 200.00

Medicine Details

Category	Details
Generic	Cefuroxime axetil
Company	Ibn sina pharmaceuticals ltd
Also available as	Merocef 250 mg tablet Merocef 500 mg tablet Merocef 750 mg injection

Cefuroxime is a well-characterized and effective antibacterial agent, which has broad-spectrum bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains.

Pharyngitis/Tonsillitis caused by Streptococcus pyogenes
Acute Bacterial Otitis Media caused by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis (beta-lactamase producing strains) or Streptococcus pyogenes
Acute bacterial maxillary sinusitis caused by Streptococcus pneumoniae or Haemophilus influenzae (non beta-lactamase producing strains)
Lower respiratory tract infections including pneumoniae, caused by Streptococcus pneumoniae, Haemophilus influenzae (including beta lactamase-producing strains), Klebsiella spp., Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), Streptococcus pyogenes, E. coli
Acute bacterial exacerbation of chronic bronchitis and Secondary bacterial infections of Acute bronchitis caused by Streptococcus pneumoniae, Haemophilus influenzae (beta-lactamase negative strains) or Haemophilus parainfluenzae (beta-lactamase negative strains)
Skin and skin-structure infections caused by Staphylococcus aureus (including beta-lactamase producing strains) or Streptococcus pyogenes
Urinary tract infections caused by E.coli or Klebsiella pneumoniae
Bone and Joint Infections caused by Staphylococcus aureus (penicillinase- and non-penicillinase-producing strains)
Gonorrhoea caused by penicillinase-producing and non-penicillinase producing strains of Neisseria gonorrhoeae
Early Lyme Disease (erythema migrans) caused by Borrelia burgdorferi

250 mg b.i.d. for 5-10 days for adolescents and adults (Pharyngitis/Tonsillitis)
250 mg b.i.d. for 10 days for adolescents and adults (Acute bacterial maxillary sinusitis)
250-500 mg b.i.d. for 10 days for adolescents and adults (Acute bacterial exacerbation of chronic bronchitis)
250-500 mg b.i.d. for 5-10 days for adolescents and adults (Secondary bacterial infections of Acute bronchitis)
250-500 mg b.i.d. for 10 days for adolescents and adults (Uncomplicated skin and skin structure infections)
250 mg b.i.d. for 7-10 days for adolescents and adults (Uncomplicated urinary tract infections)
1000 mg Single dose for uncomplicated Gonorrhoea in adolescents and adults
250-500 mg b.i.d. for 5-10 days for adolescents and adults (Community acquired pneumonia)
500 mg b.i.d. for 10-14 days in adolescents and adults (MDR Typhoid Fever)
500 mg b.i.d. for 20 days in adolescents and adults (Early Lyme disease)
20 mg/kg/day b.i.d for 5-10 days for paediatric patients (Pharyngitis/Tonsillitis)
30 mg/kg/day b.i.d for 10 days for paediatric patients (Acute otitis media)
30 mg/kg/day b.i.d for 10 days for paediatric patients (Acute bacterial maxillary sinusitis)
30 mg/kg/day b.i.d for 10 days for paediatric patients (Impetigo)

The use of freshly reconstituted solution is recommended. However, it maintains potency for at least 24 hours at room temperature or 48 hours at 5<sup>o</sup> C.Pregnancy & Lactation- US FDA pregnancy category of Cefuroxime is B. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Cefuroxime have been shown to be excreted in human milk. So, caution should be exercised when Cefuroxime is administered to a nursing woman.

Adverse effects to Merocef have occurred infrequently and have been generally mild and transient in nature. Effects reported include rashes and gastrointestinal disturbances. As with other antibiotics, prolonged use may result in the overgrowth of non susceptible organisms e.g. Candida.

Store in a cool, dry place (below 30<sup>o</sup> C), away from light & moisture. Keep out of the reach of children.

Cefuroxime is a well-characterized and effective antibacterial agent, which has broad-spectrum bactericidal activity against a wide range of common pathogens, including β-lactamase producing strains. Cefuroxime has good stability to bacterial β-lactamase and consequently, is active against many ampicillin-resistant and amoxycillin-resistant strains.

Merocef should be given with care to patients receiving concurrent treatment with potent diuretics & who has history of colitis. Cephalosporin antibiotics may in general be given safely to patients who are hypersensitive to penicillin although cross reactions have reported. Merocef has shown, that is not likely to be a problem at the recommended to dose levels.